People With Type 2 Diabetes Achieve Superior Outcomes With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
People With Type 2 Diabetes Achieve Superior Outcomes With Insulin Pumps vs. Multiple Daily Injections

BRAMPTON, ON --(Marketwired - July 02, 2014) - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. ( NYSE : MDT ) today announced the results of the global OpT2mise trial, which included eight participating centres in Canada. The results showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections. While the benefits of continuous subcutaneous insulin infusion (CSII) with an insulin pump for people with type 1 diabetes are well proven, this is the largest global study to evaluate the comparative efficacy of CSII with an insulin pump versus multiple daily insulin injections in people with type 2 diabetes with poor glycemic control. Study results were published online in The Lancet today.

In the OpT2mise trial, those using insulin pumps achieved a mean A1C (average blood glucose) reduction of 1.1 percent compared to only a 0.4 percent reduction by those using multiple daily injections. This improvement in glucose control was achieved without any episodes of severe hypoglycemia. In addition, those in the insulin pump group lowered the total daily dose of insulin by more than 20 percent. There was no difference in weight gain between the two groups.

Reducing A1C is critical for people with diabetes because even small percent drops aid significantly in preventing complications, such as eye disease, kidney disease, nerve damage and heart attacks 1, 2 .

 "For these patients, insulin pump technology is therefore a valuable option with proven benefits over simply continuing adjustments of an MDI (multiple daily injection) regimen," said Dr. Ronnie Aronson of LMC Diabetes & Endocrinology, Toronto, Canada, one of the study authors. "Insulin pump use can safely reduce HbA1c, with less insulin, and without increasing hypoglycemia and should take a spot in the care path for our type 2 diabetes patients who need advanced insulin management." 

Approximately 20 million people around the world with type 2 diabetes require insulin replacement therapy and adherence to insulin therapy can be a challenge, with 57% of patients on MDI therapy admitting to omitting insulin injections 3 .

The global, randomized, controlled study was sponsored by Medtronic and conducted with participation from 331 patients, ranging in age from 30 to 75 years. Eight centres across Canada participated in the study. Specific results include:

  • Those using insulin pumps demonstrated a mean reduction of A1C levels by 1.1 percent, vs. only 0.4 percent for participants using multiple daily injections ( P  < 0.001).
  • Those in the CSII arm experienced the A1C reduction without any episodes of severe hypoglycemia (low blood sugar, which can cause confusion, disorientation, loss of consciousness, and in the worst cases coma and even death) or ketoacidosis (a potentially life-threatening condition caused by hyperglycemia or high blood sugar).
  • The total daily insulin dose was 20.4% lower with CSII than with injection therapy ( P  < 0.001) with no significant difference in body weight change between the two groups.
  • The percentage of participants in the CSII group achieving an A1C < 8% was twice that of the multiple daily injections group (55% vs. 28%).

"As Medtronic continues to expand into providing more solutions for people living with type 2 as well as type 1 diabetes, collaborating with the world's experts to build a clinical body of evidence to help guide therapy for all people with diabetes is very important," said Francine R. Kaufman, M.D., Chief Medical Officer and Vice President of Global, Clinical and Medical Affairs for Medtronic Diabetes. "OpT2mise is the latest example of this clinical leadership and a trial that has the potential to help improve access to insulin pump technology for the many people with type 2 diabetes who could benefit."

About the Diabetes Business at Medtronic of Canada

The Diabetes business at Medtronic of Canada ( www.medtronicdiabetes.ca ) is the Canadian leader in advanced glucose monitoring and control solutions, including insulin pump technology, continuous glucose monitoring systems and therapy management software, as well as world-class, 24/7 consumer and professional service and support. 

About Medtronic of Canada

Medtronic of Canada Ltd. ( www.medtronic.ca ) is a trusted Canadian leader delivering innovative health system solutions and advanced medical technologies to alleviate pain, restore health, and extend life in the areas of cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose, throat surgery. Medtronic is proud to employ more than 700 Canadians. Headquartered in Brampton, Ontario, Medtronic has regional offices in Vancouver and Montreal, including a manufacturing facility, Medtronic CryoCath, located in Pointe-Claire, Quebec.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853

2 The post trial monitoring results: 10 years follow up: Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med; 359:1577-1589

3 Peyrot et al (2010) Correlates of insulin injection omission, Diabetes Care 33:240-245 .

Contact: Melicent Lavers-Sailly Public Relations 905-460-3653

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 50

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

Cryptocurrency Market Update: Bitcoin and Ethereum Trends

Updated Category News Views 289

Cryptocurrency Market Overview As of Tuesday morning, the cryptocurrency market is experiencing a decline, with Bitcoin's price falling to $113,000 amidst ongoing negotiations regarding a government shutdown in the U.S. This pivotal moment has left investors analyzing market movements closely. Key Cryptocurrency Prices The current prices for major cryptocurrencies are as...

Continue Reading
Kinross Gold Corporation Invests in Relevant Gold Shares

Updated Category News Views 169

Kinross Gold Corporation Makes Strategic Investment in Relevant Gold Kinross Gold Corporation, commonly referred to as Kinross, has made headlines by agreeing to acquire a substantial position in Relevant Gold Corp. This move reinforces Kinross's commitment to strategic growth in the gold mining sector. The transaction involves the purchase of 15,410,000 shares at a price...

Continue Reading
Mark Cuban's Insights: Bitcoin Maximalism and Whirlwinds of ETFs

Updated Category News Views 167

Mark Cuban Reflects on Bitcoin Dynamics Billionaire investor and well-known entrepreneur Mark Cuban recently shared his reflections on the Bitcoin ecosystem. He highlighted a perceived contradiction within the Bitcoin community regarding their stance on regulation versus their eagerness for exchange-traded funds (ETFs). This dialogue is not just a casual observation; it...

Continue Reading
Understanding the Class Action for Pacira BioSciences Shareholders

Updated Category News Views 114

Overview of Pacira BioSciences Class Action Pacira BioSciences, Inc. (NASDAQ: PCRX) is currently facing a significant class action lawsuit that has garnered attention from shareholders who have experienced financial losses. The core issue stems from a recent patent infringement case in which Pacira's main patent for Exparel was deemed invalid, which raises concerns about...

Continue Reading
Innovative Eyewear Location Feature Revolutionizes Searching

Updated Category News Views 98

Innovative Solution for Locating Eyewear In our fast-paced lives, finding misplaced items can be a hassle, especially when it comes to something essential like eyewear. An inventive solution has emerged for this common issue. An inventor, inspired by his personal experiences, has developed a game-changing product known as the I SEE YOU. This device is designed...

Continue Reading